1
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidence and mortality worldwide: Sources, methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015.
View Article : Google Scholar : PubMed/NCBI
|
2
|
Engholm G, Ferlay J, Christensen N, Kejs
AMT, Hertzum-Larsen R, Johannesen TB, Khan S, Leinonen MK,
Ólafsdóttir E, Petersen T, et al: 2016 NORDCAN: Cancer Incidence,
Mortality, Prevalence and Survival in the Nordic Countries, Version
7.3 (08.07.2016). Association of the Nordic Cancer Registries.
Danish Cancer Society. http://www.ancr.nuMarch 19–2017
|
3
|
Hadji P: Cancer treatment-induced bone
loss in women with breast cancer. Bonekey Rep. 4:6922015.
View Article : Google Scholar : PubMed/NCBI
|
4
|
Hernlund E, Svedbom A, Ivergård M,
Compston J, Cooper C, Stenmark J, McCloskey EV, Jönsson B and Kanis
JA: Osteoporosis in the European Union: Medical management,
epidemiology and economic burden. A report prepared in
collaboration with the International Osteoporosis Foundation (IOF)
and the European Federation of Pharmaceutical Industry Associations
(EFPIA). Arch Osteoporos. 8:1362013. View Article : Google Scholar : PubMed/NCBI
|
5
|
Cameron DA, Douglas S, Brown JE and
Anderson RA: Bone mineral density loss during adjuvant chemotherapy
in pre-menopausal women with early breast cancer: Is it dependent
on oestrogen deficiency? Breast Cancer Res Treat. 123:805–814.
2010. View Article : Google Scholar : PubMed/NCBI
|
6
|
Hershman DL, McMahon DJ, Crew KD, Shao T,
Cremers S, Brafman L, Awad D and Shane E: Prevention of bone loss
by zoledronic acid in premenopausal women undergoing adjuvant
chemotherapy persist up to one year following discontinuing
treatment. J Clin Endocrinol Metab. 95:559–566. 2010. View Article : Google Scholar : PubMed/NCBI
|
7
|
Canalis E, Mazziotti G, Giustina A and
Bilezikian JP: Glucocorticoid-induced osteoporosis: Pathophysiology
and therapy. Osteoporos Int. 18:1319–1328. 2007. View Article : Google Scholar : PubMed/NCBI
|
8
|
Christensen CØ, Cronin-Fenton D, Frøslev
T, Hermann AP and Ewertz M: Change in bone mineral density during
adjuvant chemotherapy for early-stage breast cancer. Support Care
Cancer. 24:4229–4236. 2016. View Article : Google Scholar : PubMed/NCBI
|
9
|
Kalder M and Hadji P: Breast cancer and
osteoporosis-management of cancer treatment-induced bone loss in
postmenopausal women with breast cancer. Breast Care (Basel).
9:312–317. 2014. View Article : Google Scholar : PubMed/NCBI
|
10
|
Greep NC, Giuliano AE, Hansen NM, Taketani
T, Wang HJ and Singer FR: The effects of adjuvant chemotherapy on
bone density in postmenopausal women with early breast cancer. Am J
Med. 114:653–659. 2003. View Article : Google Scholar : PubMed/NCBI
|
11
|
Bjarnason NH, Hitz M, Jorgensen NR and
Vestergaard P: Adverse bone effects during pharmacological breast
cancer therapy. Acta Oncol. 47:747–754. 2008. View Article : Google Scholar : PubMed/NCBI
|
12
|
Chen Y, Xu G and Yang F: Effect of
neoadjuvant chemotherapy on the serum levels of bone turnover
markers in women with early-stage breast cancer. PLoS One.
10:e01260532015. View Article : Google Scholar : PubMed/NCBI
|
13
|
Hadji P: Aromatase inhibitor-associated
bone loss in breast cancer patients is distinct from postmenopausal
osteoporosis. Crit Rev Oncol Hematol. 69:73–82. 2009. View Article : Google Scholar : PubMed/NCBI
|
14
|
Eastell R, Adams JE, Coleman RE, Howell A,
Hannon RA, Cuzick J, Mackey JR, Beckmann MW and Clack G: Effect of
anastrozole on bone mineral density: 5-year results from the
anastrozole, tamoxifen, alone or in combination trial 18233230. J
Clin Oncol. 26:1051–1057. 2008. View Article : Google Scholar : PubMed/NCBI
|
15
|
Kanis JA, McCloskey EV, Powles T, Paterson
AH, Ashley S and Spector T: A high incidence of vertebral fracture
in women with breast cancer. Br J Cancer. 79:1179–1181. 1999.
View Article : Google Scholar : PubMed/NCBI
|
16
|
Love RR, Mazess RB, Barden HS, Epstein S,
Newcomb PA, Jordan VC, Carbone PP and DeMets DL: Effects of
tamoxifen on bone mineral density in postmenopausal women with
breast cancer. N Engl J Med. 326:852–856. 1992. View Article : Google Scholar : PubMed/NCBI
|
17
|
Yoneda K, Tanji Y, Ikeda N, Miyoshi Y,
Taguchi T, Tamaki Y and Noguchi S: Influence of adjuvant tamoxifen
treatment on bone mineral density and bone turnover markers in
postmenopausal breast cancer patients in Japan. Cancer Lett.
186:223–230. 2002. View Article : Google Scholar : PubMed/NCBI
|
18
|
Vehmanen L, Elomaa I, Blomqvist C and
Saarto T: Tamoxifen treatment after adjuvant chemotherapy has
opposite effects on bone mineral density in premenopausal patients
depending on menstrual status. J Clin Oncol. 24:675–680. 2006.
View Article : Google Scholar : PubMed/NCBI
|
19
|
Early Breast Cancer Trialists
Collaborative Group (EBCTCG): Adjuvant bisphosphonate treatment in
early breast cancer: Meta-analyses of individual patient data from
randomised trials. Lancet. 386:1353–1361. 2015. View Article : Google Scholar : PubMed/NCBI
|
20
|
Shapiro CL, Manola J and Leboff M: Ovarian
failure after adjuvant chemotherapy is associated with rapid bone
loss in women with early-stage breast cancer. J Clin Oncol.
19:3306–3311. 2001. View Article : Google Scholar : PubMed/NCBI
|
21
|
Hadji P, Gnant M, Body JJ, Bundred NJ,
Brufsky A, Coleman RE, Guise TA, Lipton A and Aapro MS: Cancer
treatment-induced bone loss in premenopausal women: A need for
therapeutic intervention? Cancer Treat Rev. 38:798–806. 2012.
View Article : Google Scholar : PubMed/NCBI
|
22
|
Garg MK and Kharb S: Dual energy X-ray
absorptiometry: Pitfalls in measurement and interpretation of bone
mineral density. Indian J Endocrinol Metab. 17:203–210. 2013.
View Article : Google Scholar : PubMed/NCBI
|
23
|
Marshall D, Johnell O and Wedel H:
Meta-analysis of how well measures of bone mineral density predict
occurrence of osteoporotic fractures. BMJ. 312:1254–1259. 1996.
View Article : Google Scholar : PubMed/NCBI
|
24
|
Riggs BL, Khosla S and Melton LJ III: Sex
steroids and the construction and conservation of the adult
skeleton. Endocr Rev. 23:279–302. 2002. View Article : Google Scholar : PubMed/NCBI
|
25
|
Hershman DL, McMahon DJ, Crew KD, Cremers
S, Irani D, Cucchiara G, Brafman L and Shane E: Zoledronic acid
prevents bone loss in premenopausal women undergoing adjuvant
chemotherapy for early-stage breast cancer. J Clin Oncol.
26:4739–4745. 2008. View Article : Google Scholar : PubMed/NCBI
|